FindTrial
Sign In

Effects and safety of MMF combined with short course steriods therapy in children Henoch-Schnlein purpura nephritis

Effects and safety of MMF combined with short course steriods therapy in children Henoch-Schnlein purpura nephritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037540
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-09-30
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children Henoch-Schnlein purpura nephritis

Interventions

experimental group:mycophenolate mofetil
control group:traditional course steriod

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Aged less than 14 years; 2. Henoch-Sch?nlein purpura nephritis; 3. ISKDC grade III; 4. Approval informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mycophenolate, cyclophosphamide and tacrolimus had been used before enrollment; 2. A history of mycophenolate Mofel drug allergy; 3. Immunodeficiency.

Design outcomes

Primary

MeasureTime frame
proteinuria;—

Secondary

MeasureTime frame
renal function;—

Countries

China

Contacts

Public ContactYufeng Li

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

liyufeng@xinhuamed.com.cn+86 13651722016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026